Brand Name

Xadago

Generic Name
Safinamide
View Brand Information
FDA approval date: May 08, 2017
Classification: Monoamine Oxidase Type B Inhibitor
Form: Tablet

What is Xadago (Safinamide)?

XADAGO is indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing "off" episodes. XADAGO is a monoamine oxidase type B inhibitor indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing "off" episodes

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

Advanced Parkinson's disease treatment patterns in Italy: results from a multicenter observational study.
Advanced Parkinson's disease treatment patterns in Italy: results from a multicenter observational study.
Journal: Annals of medicine
Published: March 05, 2026
Antiseizure Medications that Did Not Reach the Epilepsy Market: An Assessment of Factors Contributing to Their Failed Clinical Development Over the Last Three Decades.
Antiseizure Medications that Did Not Reach the Epilepsy Market: An Assessment of Factors Contributing to Their Failed Clinical Development Over the Last Three Decades.
Journal: Drugs
Published: November 26, 2025
Efficacy of MAO-B and COMT inhibitors on quality of life in patients with Parkinson's disease: a Bayesian network meta-analysis.
Efficacy of MAO-B and COMT inhibitors on quality of life in patients with Parkinson's disease: a Bayesian network meta-analysis.
Journal: Frontiers in neurology
Published: November 24, 2025
View All Latest Advances